Search

Your search keyword '"Hébert V"' showing total 190 results
Start Over Author "Hébert V"
190 results on '"Hébert V"'

6. Actualisation des recommandations françaises de traitement du pemphigus

Author

Jelti, L., Prost-Squarcioni, C., Ingen-Housz-Oro, S., Caux, F., Bernard, P., Bedane, C., Alexandre, M., Dereure, O., Quereux, G., Le Bidre, E., Plée, J., Picard-Dahan, C., Le Roux-Villet, C., Duvert-Lehembre, S., Richard, M.-A., Delaporte, E., Debarbieux, S., Jullien, D., D’Incan, M., Konstantinou, M.-P., Bouaziz, J.-D., Tancrède-Bohin, E., Doutre, M.-S., Bourgault Villada, I., Cordel, N., Sassolas, B., Viguier, M.-A., Mellottée, B., Jouen, F., Hebert, V., and Joly, P.

Published
2019
Full Text
View/download PDF

12. Efficacité et tolérance à long terme des schémas thérapeutiques testés chez les patients atteints de pemphigus inclus dans l’essai clinique Ritux 3

Author

Tedbirt, B., primary, Maho-Vaillant, M., additional, Houivet, E., additional, Calbo, S., additional, Prost-Squarcioni, C., additional, Labeille, B., additional, Picard-Dahan, C., additional, Konstantinou, M.P., additional, Chaby, G., additional, Richard, M.A., additional, Bouaziz, J.D., additional, Duvert Lehembre, S., additional, Delaporte, E., additional, Bernard, P., additional, Caux, F., additional, Alexandre, M., additional, Oro, S., additional, Vabres, P., additional, Quéreux, G., additional, Dupuy, A., additional, Debarbieux, S., additional, Avenel-Audran, M., additional, D’Incan, M., additional, Bedane, C., additional, Beneton, N., additional, Jullien, D., additional, Dupin, N., additional, Misery, L., additional, Machet, L., additional, Beylot-Barry, M., additional, Dereure, O., additional, Sassolas, B., additional, Benichou, J., additional, Joly, P., additional, and Hébert, V., additional

Published
2022
Full Text
View/download PDF

14. Understanding the Tropospheric Transport and Fate of Agricultural Pesticides

Author

Hebert, V. R., Miller, G. C., Ware, George W., editor, Albert, Lilia A., editor, Crosby, D. G., editor, de Voogt, Pim, editor, Hutzinger, O., editor, Knaak, James B., editor, Mayer, Foster L., editor, Morgan, D. P., editor, Park, Douglas L., editor, Tjeerdema, Ronald S., editor, Yang, Raymond S. H., editor, and Gunther, Francis A., editor

Published
2004
Full Text
View/download PDF

31. Pemphigoïdes bulleuses associées aux anti-PD-1/PDL-1 : étude nationale de 85 cas

Author

Juzot, C., primary, Sibaud, V., additional, Amatore, F., additional, Mansard, S., additional, Seta, V., additional, Jeudy, G., additional, Pham-Ledard, A., additional, Benzaquen, M., additional, Dinulescu, M., additional, Le Corre, Y., additional, Lesage, C., additional, Viguier, M., additional, Baroudjian, B., additional, Clerc, C.-J., additional, Funck-Brentano, E., additional, Giacchero, D., additional, Mortier, L., additional, Peuvrel, L., additional, Machet, L., additional, Duvert-Lehembre, S., additional, Viarnaud, A., additional, Joachim, C., additional, Bara, C., additional, Baubion, E., additional, Bergeret, B., additional, Brunet-Possenti, F., additional, Debarbieux, S., additional, Hébert, V., additional, Konstantinou, M.-P., additional, Marzouki-Zerouali, A., additional, Moreau-Huguen, J., additional, Phan, C., additional, Templier, I., additional, Celerier, P., additional, Aubin, F., additional, Modiano, P., additional, Poinas, A., additional, Vibet, M.-A., additional, Dréno, B., additional, and Quéreux, G., additional

Published
2020
Full Text
View/download PDF

35. Sensitivity to change and correlation between the autoimmune bullous disease quality‐of‐life questionnaires ABQOL and TABQOL , and objective severity scores

Author

Ferries, L., primary, Gillibert, A., additional, Duvert‐Lehembre, S., additional, Corbaux, C., additional, Alexandre, M., additional, Prost‐Squarcioni, C., additional, Caux, F., additional, Delaporte, E., additional, Litrowski, N., additional, Boulard, C., additional, Murrell, D.F., additional, Joly, P., additional, and Hébert, V., additional

Published
2020
Full Text
View/download PDF

36. Risk factors for treatment failure in scabies: a cohort study

Author

Aussy, A., Houivet, E., Hébert, V., Colas‐Cailleux, H., Laaengh, N., Richard, C., Ouvry, M., Boulard, C., Leger, S., Litrowski, N., Bénichou, J., Joly, P., Béchu, Stéphane, Mion‐Mouton, N., Lafaurie, O., Barrel, A., Pulluard, M., Hamel, V., Dore, M.X., Duflo, E., Lardans‐Cassius, S., Rzeznik, J.C., Baricault, S., Unité de biostatistiques [CHU Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU), Service de Dermatologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Hôpital Charles Nicolle [Rouen], Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Photochimie moléculaire et macromoléculaire (PMM), Centre National de la Recherche Scientifique (CNRS)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Institut de Chimie du CNRS (INC), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Alcatel-Thalès III-V lab (III-V Lab), THALES-ALCATEL, Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM ), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry]), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), THALES [France]-ALCATEL, and Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, [SDV]Life Sciences [q-bio], Administration, Oral, Beds, Dermatology, Administration, Cutaneous, Benzoates, Risk Assessment, Drug Administration Schedule, Cohort Studies, Scabies, Young Adult, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Ivermectin, Pharmacotherapy, Risk Factors, Internal medicine, Animals, Humans, Medicine, Treatment Failure, Child, Decontamination, ComputingMilieux_MISCELLANEOUS, Antiparasitic Agents, business.industry, Incidence (epidemiology), Infant, Odds ratio, medicine.disease, Confidence interval, 3. Good health, Child, Preschool, Ambulatory, [SDV.IMM]Life Sciences [q-bio]/Immunology, Drug Therapy, Combination, Female, France, Sarcoptes scabiei, business, Cohort study, medicine.drug
Abstract

Background Treatment failure, which occurs in about one-third of cases, is considered as a major factor in the increasing incidence of scabies in developed countries. Objectives To identify predictors of treatment failure of scabies in ambulatory populations. Methods This multicentre study compared the clinical characteristics and treatment modalities between a group of patients with scabies treated successfully and another group who were not cured 3 months after antiscabies treatment. Results In total 210 patients with a diagnosis of scabies were included, comprising 98 patients in the treatment success group and 112 in the treatment failure group. The main risk factors for treatment failure were (i) the use of only one type of treatment, topical benzyl benzoate (BB) or oral ivermectin, vs. the combination of both treatments [odds ratio (OR) 2·15, 95% confidence interval (CI) 1·22-3·77]; (ii) the use of a single intake (vs. two) of oral ivermectin (OR 10·2. 95% CI 4·49-23·2); (iii) intake of ivermectin during a meal vs. on an empty stomach (OR 4·31, 95% CI 1·89-9·84); (iv) absence of decontamination of furnishings (OR 8·72, 95% CI 3·50-21·8), in particular sofa and cushions (OR 5·90, 95% CI 2·34-14·9), mattresses (OR 4·16, 95% CI 1·35-12·8) or car seats (OR 6·57, 95% CI 3·27-13·2) and (v) absence of written documents explaining treatment modalities (OR 5·18, 95% CI 2·57-10·4). In multivariate analysis, treatment failure was mainly associated with (i) use of a single intake (vs. two) of ivermectin (OR 6·62, 95% CI 2·71-16·2); (ii) use of BB alone vs. two intakes of ivermectin (OR 3·51, 95% CI 1·55-7·95) and (iii) absence of decontamination of furniture with acaricides (OR 5·81, 95% CI 1·96-16·7). Conclusions Use of topical BB alone and a single intake (vs. two) of ivermectin are predictors of treatment failure.

Published
2019
Full Text
View/download PDF

37. Efficacité d’un traitement par ipilimumab/nivolumab ou thérapie ciblée en traitement de rattrapage après échappement sous nivolumab utilisé en adjuvant : étude descriptive sur 18 patients

Author

Janela-Lapert, R., Duval-Modeste, A.B., Claire, M., Lafon, A., and Hébert, V.

Abstract

Les inhibiteurs de checkpointimmunitaire anti-PD1 sont les traitements de référence du mélanome métastatique BRAF sauvage. Ils sont désormais disponibles à des stades de plus en plus précoces, permettant une meilleure survie globale. Malheureusement, malgré leur utilisation précoce en adjuvant, les échappements ne sont pas rares et la stratégie de rattrapage n’est pas codifiée. Évaluer l’efficacité du traitement par ipilimumab et nivolumab (IPI/NIVO) ou thérapie ciblée anti-BRAF/anti-MEK (TC) chez les patients ayant récidivé malgré un traitement adjuvant par anti-PD1.

Published
2024
Full Text
View/download PDF

38. International multicentre observational study to assess the efficacy and safety of a 0·5 mg kg−1 per day starting dose of oral corticosteroids to treat bullous pemphigoid.

Author

Hébert, V., Bastos, S., Drenovska, K., Meijer, J., Ingen‐Housz‐Oro, S., Bedane, C., Lunardon, L., Debarbieux, S., Jedlickova, H., Caux, F., Chaby, G., D'Incan, M., Feliciani, C., Boulard, C., Schumacher, N., Schmidt, E., Roussel, A., Richard, M.A., Gottlieb, J., and Ferranti, V.

Subjects
*BULLOUS pemphigoid, *KARNOFSKY Performance Status, *CORTICOSTEROIDS, *SCIENTIFIC observation, *OVERALL survival
Abstract

Summary: Background: European guidelines propose a 0·5 mg kg−1 per day dose of oral prednisone as initial treatment for bullous pemphigoid (BP). We assessed the safety and efficacy of this regimen depending on BP extent and general condition of the patients. Methods: In a prospective international study, we consecutively included all patients diagnosed with BP. Patients received a 0·5 mg kg−1 per day dose of prednisone, which was then gradually tapered 15 days after disease control, with the aim of stopping prednisone or maintaining minimal treatment (0·1 mg kg−1 per day) within 6 months after the start of treatment. The two coprimary endpoints were control of disease activity at day 21 and 1‐year overall survival. Disease severity was assessed according to the Bullous Pemphigoid Disease Area Index (BPDAI) score. Results: In total, 198 patients were included between 2015 and 2017. The final analysis comprised 190 patients with a mean age of 80·9 (SD 9·1) years. Control of disease activity was achieved at day 21 in 119 patients [62·6%, 95% confidence interval (CI) 55·3–69.5]; 18 of 24 patients (75%, 95% CI 53·3–90·2), 75 of 110 patients (68·8%, 95% CI 59·2–77·3) and 26 of 56 patients (46.4%, 95% CI 33·0–60·3) had mild, moderate and severe BP, respectively (P = 0·0218). A total of 30 patients died during the study. The overall Kaplan–Meier 1‐year survival was 82·6% (95% CI 76·3–87·4) corresponding to 90·9%, 83·0% and 80·0% rates in patients with mild, moderate and severe BP, respectively (P = 0·5). Thresholds of 49 points for BPDAI score and 70 points for Karnofsky score yielded maximal Youden index values with respect to disease control at day 21 and 1‐year survival, respectively. Conclusions: A 0·5 mg kg−1 per day dose of prednisone is a valuable therapeutic option in patients with mild or moderate BP whose general condition allows them to be autonomous. What is already known about this topic? Superpotent topical corticosteroids are the gold standard treatment for bullous pemphigoid (BP), whatever the severity.High doses of oral corticosteroids are effective but poorly tolerated in patients with BP.Medium doses of oral corticosteroids are effective in paucibullous BP, but their efficacy in severe forms has not yet been assessed. What does this study add? Medium doses of oral corticosteroids have poor efficacy in severe BP.A baseline Bullous Pemphigoid Disease Area Index score < 50 and a Karnofsky score ≥ 70 are predictors of treatment efficacy and low mortality, respectively. Linked Comment: H.Y. Lee. Br J Dermatol 2021; 185:1093–1094. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

40. Corrélations entre les questionnaires de qualité de vie spécifiques aux maladies bulleuses auto-immunes ABQOL et TABQOL, et les scores de sévérité objectifs

Author

Ferries, L., primary, Gilibert, A., additional, Alexandre, M., additional, Duvert-Lehembre, S., additional, Corbaux, C., additional, Hébert, V., additional, Prost-Squarcioni, C., additional, Caux, F., additional, Delaporte, E., additional, Litrowski, N., additional, Boulard, C., additional, Murrell, D., additional, and Joly, P., additional

Published
2019
Full Text
View/download PDF

41. Facteurs pronostiques de rechute à long terme chez les patients atteints de pemphigus traités par rituximab en première ligne

Author

Mignard, C., primary, Maho-Vaillant, M., additional, Prost-Squarcioni, C., additional, Calbo, S., additional, Golinski, M.-L., additional, Labeille, B., additional, Picard-Dahan, C., additional, Konstantinou, M.P., additional, Richard, M.-A., additional, Bouaziz, J.D., additional, Duvert-Lehembre, S., additional, Bernard, P., additional, Caux, F., additional, Alexandre, M., additional, Oro, S., additional, Vabres, P., additional, Quereux, G., additional, Dupuy, A., additional, Debarbieux, S., additional, Martin, L., additional, D’Incan, M., additional, Bedane, C., additional, Bénéton, N., additional, Jullien, D., additional, Dupin, N., additional, Misery, L., additional, Machet, L., additional, Beylot-Barry, M., additional, Dereure, O., additional, Sassolas, B., additional, Hébert, V., additional, and Joly, P., additional

Published
2019
Full Text
View/download PDF

43. 单一典型的毛发镜检特征可预测头癣

Author

Dhaille, F., primary, Dillies, A.‐S., additional, Dessirier, F., additional, Reygagne, P., additional, Diouf, M., additional, Balthazard, T., additional, Lombart, F., additional, Hébert, V., additional, Chopinnaud, M., additional, Verneuil, L., additional, Becquart, C., additional, Delaporte, E., additional, Lok, C., additional, and Chaby, G., additional

Published
2019
Full Text
View/download PDF

44. Single typical trichoscopic feature predictive of tinea capitis

Author

Dhaille, F., primary, Dillies, A.‐S., additional, Dessirier, F., additional, Reygagne, P., additional, Diouf, M., additional, Balthazard, T., additional, Lombart, F., additional, Hébert, V., additional, Chopinnaud, M., additional, Verneuil, L., additional, Becquart, C., additional, Delaporte, E., additional, Lok, C., additional, and Chaby, G., additional

Published
2019
Full Text
View/download PDF

47. A single typical trichoscopic feature is predictive of tinea capitis: a prospective multicentre study

Author

Dhaille, F., primary, Dillies, A.‐S., additional, Dessirier, F., additional, Reygagne, P., additional, Diouf, M., additional, Baltazard, T., additional, Lombart, F., additional, Hébert, V., additional, Chopinaud, M., additional, Verneuil, L., additional, Becquart, C., additional, Delaporte, E., additional, Lok, C., additional, and Chaby, G., additional

Published
2019
Full Text
View/download PDF

49. Évaluation de la trichoscopie dans le diagnostic de teigne, étude prospective multicentrique sur 2 ans, à propos de 100 patients

Author

Dhaille, F., primary, Dillies, A.-S., additional, Dessirier, F., additional, Reygagne, P., additional, Lombart, F., additional, Joly, P., additional, Hébert, V., additional, Delaporte, E., additional, Becquart, C., additional, Verneuil, L., additional, Chopinaud, M., additional, Lok, C., additional, and Chaby, G., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results